AS1842856 | FOXO1 inhibitor

Available Options

Size:PriceQuantity 
5 mg$60.00
25 mg$190.00
Request Quote / Bulk / Custom Size
Product Inquiry

AS1842856 (836620-48-5) potent and selective FOXO1 inhibitor, IC50s=33 nM and >1 mM for FOXO3a and 4.1 Oral administration to diabetic db/db mice leads to a reduction of fasting plasma glucose levels.1 Suppresses autophagy, FSP27 expression and adipocyte differentiation.2 AS1842856 is a highly useful tool for probing the involvement of FOXO1 in cellular processes.3-5

References/Citations:

  1. Nagashima et al. (2010), Discovery of novel forkhead box O1 inhibitors for treating type 2 diabetes: improvement of fasting glycemia in diabetic db/dbmice; Mol. Pharmacol. 78 961
  2. Liu et al. (2016), FoxO1 antagonist suppresses autophagy and lipid droplet growth in adipocytes; Cell Cycle 15 2033
  3. Galley et al. (2019), Antagonism of Forkhead Box Subclass O Transcription Factors Elicits Loss of Soluble Guanylyl Cyclase Expression; Mol. Pharmacol. 95 629
  4. Chen et al. (2024), SIRT1 silencing ameliorates malignancy of non-small cell lung cancer via activating FOXO1; Sci. Rep. 14 19948
  5. Yang et al. (2023), Suppression of FOXO1 attenuates inflamm-aging and improves liver function during aging; Aging Cell 22 e13968
836620-48-5, AS 1842856, AS1842856, AS1842856 supplier, Forkhead Box inhibitor, FOXO1 inhibitor

Safety Data Sheet:

N/A

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

AS1842856 (836620-48-5) potent and selective FOXO1 inhibitor, IC50s=33 nM and >1 mM for FOXO3a and 4.1 Oral administration to diabetic db/db mice leads to a reduction of fasting plasma glucose levels.1 Suppresses autophagy, FSP27 expression and adipocyte differentiation.2 AS1842856 is a highly useful tool for probing the involvement of FOXO1 in cellular processes.3-5

References/Citations:

  1. Nagashima et al. (2010), Discovery of novel forkhead box O1 inhibitors for treating type 2 diabetes: improvement of fasting glycemia in diabetic db/dbmice; Mol. Pharmacol. 78 961
  2. Liu et al. (2016), FoxO1 antagonist suppresses autophagy and lipid droplet growth in adipocytes; Cell Cycle 15 2033
  3. Galley et al. (2019), Antagonism of Forkhead Box Subclass O Transcription Factors Elicits Loss of Soluble Guanylyl Cyclase Expression; Mol. Pharmacol. 95 629
  4. Chen et al. (2024), SIRT1 silencing ameliorates malignancy of non-small cell lung cancer via activating FOXO1; Sci. Rep. 14 19948
  5. Yang et al. (2023), Suppression of FOXO1 attenuates inflamm-aging and improves liver function during aging; Aging Cell 22 e13968

Related Transcription Factor Modulators

Download